A Study Evaluating TJ210001 in the Treatment of Subjects With Advanced Solid Tumors
A phase I clinical study evaluating TJ210001 in the treatment of subjects with advanced solid tumors
Advanced Solid Tumor
DRUG: TJ210001 Injection
Rate and Severity of Dose-limiting toxicity （DLT）, up to 28 days after last dose of study drug|Maximum tolerated dose (MTD), up to 21days following first dose
This study is a phase I clinical study evaluating TJ210001 monotherapy in patients with advanced solid tumors in dose escalation. The overall design of the study is shown in the figure below. The purpose of the TJ210001 single-dose escalation study in subjects with advanced solid tumors is to evaluate the safety and tolerability of monotherapy to determine the MTD (or MAD) and clinically recommended doses of TJ210001 monotherapy.